Concepedia

Harry Dedman

HD

4

Publications

464

Citations

4

H-Index

2009

Active since

Affiliations

Exelixis (United States)(Current)

University of California San Diego

University of Virginia Health System

Harry Dedman is an author at Exelixis (United States) specializing in metabolic syndrome, cardiovascular disease, and atherosclerosis.

Top concepts

MedicineImmunologyInflammationPharmacologyCell SignalingAtherosclerosisVascular BiologyVascular DiseaseMetabolic SyndromeCardiovascular Disease

Publications per year

2009–2024

4

Publications

4

Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P <sub>1</sub> ) and receptor‐5 (S1P <sub>5</sub> ) agonist with autoimmune disease‐modifying activity

Fiona L. Scott, Bryan Clemons, Jennifer L. Brooks et al. · British Journal of Pharmacology · 2016 · 296 citations · Full text

Non-redundant roles for LXR and LXR in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice

Eric D. Bischoff, Chris Daige, Mary Petrowski et al. · Journal of Lipid Research · 2010 · 94 citations

Inflammation, Metabolic Syndrome, Non-redundant Roles +12

Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists

Joshua Wollam, Michelle Solomon, Christiane Villescaz et al. · Journal of Allergy and Clinical Immunology · 2024 · 48 citations · Full text

Non-redundant roles for LXRα and LXRβ in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice

Eric D. Bischoff, Chris Daige, Mary Petrowski et al. · Journal of Lipid Research · 2009 · 26 citations · Full text

Rows per page

1–4 of 4